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Objective: We sought to elucidate the molecular mechanisms
underlying the clinical efficacy of tofacitinib in patients with
psoriasis.
Methods: Twelve patients with plaque psoriasis were randomized
(3:1) to receive 10 mg of tofacitinib or placebo twice daily for
12 weeks. Biopsy specimens were taken from nonlesional (baseline)
and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin.
Biopsy specimens were examined for psoriatic epidermal features
(thickness, Ki671 keratinocytes and keratin 16 [KRT16] mRNA
expression, and phosphorylated signal transducer and activator of
transcription [pSTAT]1 nuclei) and T-cell and dendritic cell (DC)
subsets by using immunohistochemistry, and mRNA transcripts
were quantified by using a microarray.
Results: In lesional skin keratinocyte pSTAT1 and pSTAT3
staining was increased at baseline but reduced after 1 day of
tofacitinib (baseline, median of 1290 pSTAT11 cells/mm2; day
1, median of 332 pSTAT11 cells/mm2; and nonlesional, median
of 155 pSTAT11 cells/mm2). Epidermal thickness and KRT16
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http://dx.doi.org/10.1016/j.jaci.2015.12.1318reduced after days 1 and 3 of tofacitinib administration,
respectively (eg, KRT16 decreased 2.74-fold, day 3 vs baseline,
P 5 .016). Decreases in DC and T-cell numbers were observed
after weeks 1 and 2, respectively. At week 4, significant
decreases in IL-23/TH17 pathways were observed that
persisted through week 12. Improvements in clinical and
histologic features were strongly associated with changes in
expression of psoriasis-related genes and reduction in IL-17
gene expression.
Conclusions: Tofacitinib has a multitiered response in patients
with psoriasis: (1) rapid attenuation of keratinocyte Janus
kinase/STAT signaling; (2) removal of keratinocyte-induced
cytokine signaling, leading to reductions in pathologic DC
and T-cell numbers to nonlesional levels; and (3) inhibition of
the IL-23/TH17 pathway. (J Allergy Clin Immunol
2016;137:1079-90.)
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Psoriasis is a chronic immune-mediated disease characterized
by epidermal hyperplasia.1 This is driven by infiltration of
T cells and dendritic cells (DCs) and associated increased cyto-
kine levels, leading to the formation and persistence of skin
plaques.1
Current opinion on the pathogenesis of psoriasis emphasizes
the role of cytokine signaling to drive a pathogenic cycle, in which
inflammatory T-cell and DC infiltrates release IL-17, IFN-g,
IL-22, and TNF, leading to the activation and proliferation of
keratinocytes.2 The stressed and dysregulated keratinocytes
release chemokines, cytokines, and antimicrobial peptides
(AMPs).2 The chemokines recruit additional myeloid DCs and
TH1 and TH17 cells, and cytokines (eg, IL-1b, IL-6, and
TNF-a) enhance the proinflammatory interactions between the
recruited DCs and T cells. The AMPs, including cathelicidin anti-
microbial peptide (LL-37), activate pathologic DCs to produce
IFN-a/b and myeloid DCs to secrete IL-12 and IL-23. These acti-
vated DCs and T cells complete the pathogenic cycle by
continuing to activate keratinocytes.2
Tofacitinib is an oral Janus kinase (JAK) inhibitor that is being
investigated for psoriasis. Tofacitinib is a small molecule with an
intracellular mechanism of action against JAKs. Phase 3 studies in
patients with moderate-to-severe chronic plaque psoriasis have
demonstrated the efficacy of 5 and 10mg of tofacitinib twice daily
in improving clinical outcomes.3-51079
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transcriptionSTAT: Signal transducer and activator of transcriptionTLDA: TaqMan Low Density ArrayTPSS: Target Plaque Severity ScoreIn kinase assays tofacitinib inhibited JAK1, JAK2, and JAK3
and, to a lesser extent, tyrosine kinase 2.6 Tofacitinib potently in-
hibited common g-chain cytokines (IL-2, IL-4, IL-7, IL-9, IL-15,
and IL-21), IFN-g, IL-6, and, to a lesser extent, IL-12 and IL-23.6
Tofacitinib also inhibited IFN-a/b and IL-22 signaling in isolated
keratinocytes in vitro (data on file; Pfizer Inc, New York, NY). In
preclinical models tofacitinib affected both innate and adaptive
immune responses and inhibited pathogenic TH17 cell differenti-
ation by inhibiting expression of IL-23 receptors.7 However,
precisely how the JAK/signal transducer and activator of tran-
scription (STAT) pathway interacts with the multiple pathways
that are central to psoriasis pathogenesis in human subjects is
not completely understood.
Although improvements in psoriasis can be monitored by
means of clinical assessment or histologic analysis, a more
detailed understanding of therapeutic responses can be attained
through the profiling of disease-related and inflammatory
mRNA. Previous studies have established that cytokine-
targeted biologics (eg, TNF-a, IL-17, or IL-23 inhibitors) are
efficacious for the treatment of psoriasis and have the ability to
inhibit a central IL-23/TH17 axis of psoriasis, with strong down-
regulation of a series of genes that are induced in keratinocytes
and other cells by these proinflammatory cytokines.8-12 Sup-
pression of ‘‘core’’ disease-defining genes as a result of treat-
ment can be demonstrated by gene profiling, which allows the
relative suppression of different proinflammatory pathways to
be quantitatively compared.13-15 This molecular analysis allows
residual expression of disease-related genes to be detected and
quantified in lesions that have resolved clinically and
histologically.
This phase 2 study aimed to elucidate the cellular and
molecular mechanisms through which tofacitinib improves
clinical manifestations of psoriasis by delineating the time course
of changes in the pathogenic cycle of psoriasis.METHODS
Patients
Eligible patients were 18 years or older with a diagnosis of moderate-
to-severe plaque-type psoriasis for 12 or more months. Patients with a
recent infection, current malignancy, or history of malignancy (except
adequately treated or excised basal/squamous cell carcinoma or cervical
carcinoma in situ) or evidence of active or latent tuberculosis infection
were excluded.Study design
This was a phase 2, randomized, placebo-controlled, double-blind study
carried out in 6 centers in the United States from March 2013 to November
2013 (clinicaltrials.gov: NCT01710046). Patients were randomized 3:1 to
receive 10 mg of oral tofacitinib or placebo twice daily for 12 weeks by using
an automated Web or telephone randomization system.
At each study visit (baseline, days 1 and 3, andweeks 1, 2, 4, and 12), punch
biopsy specimens were collected from each patient before the morning study
drug dose (full details are provided in the Methods section in this article’s On-
line Repository at www.jacionline.org). Baseline biopsy specimens were
taken from lesional and nonlesional skin; at all later study visits, biopsy spec-
imens were only taken from lesional skin. Clinical assessments at baseline and
weeks 1, 2, 4, and 12 included the Psoriasis Area and Severity Index (PASI;
overall measure of disease severity) and Target Plaque Severity Score
(TPSS; individual lesion assessment of severity of erythema, induration,
and scaling).
Immunohistochemistry and quantitative cell
counting
Procedures for immunohistochemistry and quantitative cell counting are
outlined in greater detail in the Methods section and Table E4 in this article’s
Online Repository. Biopsy specimens from lesional and nonlesional skin were
stained for phosphorylated signal transducer and activator of transcription
(pSTAT) 1 and pSTAT3, and numbers of epidermal and dermal reactive nuclei
per square millimeter were quantified by using Definiens Tissue Studio soft-
ware (Definiens AG, M€unchen, Germany). Skin biopsy specimens were also
evaluated for expression of keratin 16 (KRT16); Ki67 (MKI67); cluster of dif-
ferentiation antigens CD3, CD11c, and CD8; langerin (CD207); lysosomal-
associated membrane protein 3 (LAMP3); S100 calcium-binding protein A7
(S100A7); MX dynamin-like GTPase 1/2 (MX1/MX2); human b-defensin
(HBD2, defensin beta 4A [DEFB4A]); and S100A8/9 (S100A8), and the num-
ber of positive cells per square millimeter of epidermis was counted manually
by using National Institutes of Health Image 6.1 software (http://rsb.info.nih.
gov/nih-image).Quantitative RT-PCR and microarray analyses
RNAwas extracted from biopsy specimens by using the RNeasy Mini Kit
(Qiagen, Valencia, Calif). The quality of extracted RNA was examined by
using the Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
Calif). IL-23p40 (IL-12B) quantitative RT-PCR was performed with EZ PCR
core reagents, primers, and probes (Life Technologies, Grand Island, NY), as
previously published,16 and the result was normalized to the ribosomal pro-
tein, large P0 (RPLP0) housekeeping gene. For microarray analysis, RNA
was amplified, labeled, and hybridized by using a standard protocol (Ovation
Whole Blood Solution and Encore BiotinModule; NuGENTechnologies, San
Carlos, Calif) to GeneChip Human Genome U133A 2.0 Arrays (Affymetrix,
Santa Clara, Calif) to measure relative gene expression. The data discussed
in this publication have been deposited in the National Center for Biotech-
nology Information’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE69967.TaqMan Low Density Array analysis
Samples for quantitative RT-PCR analysis using the CustomTaqManArray
Card (Life Technologies) were processed by Asuragen (Austin, Tex), accord-
ing to the company’s standard operating procedures (full details are provided
in the Methods section and Fig E4 in this article’s Online Repository at www.
jacionline.org). A total of 192 inflammation/cytokine-related genes were
analyzed, including 185 targets, 5 normalization genes, and 2 plate controls.Statistical analysis
The study sample size was based on the objective of exploring the
relationship between efficacy end points and exploratory gene markers
and was not specifically powered for reaching statistical significance.
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tofacitinib group and 3 patients in the placebo group. The sample size of 9 for
the tofacitinib group provided an 81% probability of observing a mean
reduction in gene expression level of at least 70% among responders, whereas
a sample size of 3 for the placebo group would ensure less than 1% probability
to observe a mean reduction of 70% or more in the placebo group (further
details are provided in theMethods section in this article’s Online Repository).
Statistical analysis was carried out with R-language17 and packages available
through the Bioconductor project.18 Tofacitinib-treated patients were classi-
fied as responders or nonresponders based on expression of the KRT16 gene
in target lesions (patients with a decrease of 75% of the difference between
baseline lesional and nonlesional skin were considered responders). Longitu-
dinal profiles of clinical end points and gene expression were compared be-
tween the tofacitinib and placebo groups and between responders and
nonresponders by using mixed-effect models with time and treatment/
response as fixed factors and patient as a random effect. Comparisons of clin-
ical data and immunohistochemistry counts are presented with P values (sig-
nificance at P 5 .05). Comparisons of high-throughput data (microarray and
TaqMan Low Density Array [TLDA]) were corrected for multiple hypothesis
testing and are presented with false discovery rate (FDR) values (significance
level 5 0.1). Further details of the data handling procedures and statistical
analysis of TLDA and microarray data can be found in the Methods section
in this article’s Online Repository. Data collection and analyses were carried
out by authors from both Pfizer Inc and Rockefeller University, and therefore
the article includes data that Pfizer Inc is not responsible for validating/storing.RESULTS
Patients
Twelve patients were randomized to 10 mg of tofacitinib twice
daily (n5 9) or placebo (n5 3, see Fig E1 in this article’s Online
Repository at www.jacionline.org). One patient treated with tofa-
citinib treatment was lost to follow-up after week 4; data were
included in analyses up to this time point. Eleven patients
completed the 12-week study. Demographics and baseline char-
acteristics are reported in Table E1 in this article’s Online Repos-
itory at www.jacionline.org.Clinical and histologic markers of psoriasis
At baseline, mean PASI scores were 21.9 and 23.3 for
tofacitinib- and placebo-treated patients, respectively (Fig 1, A),
and histologic features of psoriasis were significantly increased
in lesional versus nonlesional skin in both treatment groups
(Fig 1, B-D). PASI scores decreased from baseline through
week 12 in tofacitinib-treated patients (Fig 1, A). Corresponding
improvements in histologic features of psoriasis are shown in Fig
1, B to D. Response to tofacitinib was rapid, with significant re-
ductions in epidermal thickness and Ki67 levels from baseline af-
ter 1 day of treatment (P < .05) and significant reductions in
KRT16 expression after 3 days of treatment (P < .05). All 3 mea-
sures showed progressively greater reductions from baseline
thereafter. Changes in clinical and histologic measures with pla-
cebo were generally numerically lower and highly variable over
time. The number of responders (>_75% reduction in KRT16
expression from baseline patients with a decrease of 75% of the
difference between baseline lesional and nonlesional skin were
considered responders) was 6 (75%) with tofacitinib and 1
(33%) with placebo; the reason for response in the placebo-
treated patient is unknown.
Representative histologic assessments performed on biopsy
specimens from a tofacitinib-treated responder demonstrated a
decrease in psoriasiform pattern and overall epidermal thicknessover time (Fig 2). After 3 days of treatment, KRT16 expression
was only focally present, and by week 2, the epidermis no longer
showed the presence of KRT16 in suprabasal keratinocytes. After
4 weeks, KRT16 staining was virtually nonexistent in lesional
skin, and by week 12, the overall phenotype of tofacitinib-
treated lesional skin was virtually identical to that of baseline
nonlesional skin.JAK/STAT pathway inhibition
pSTAT expression was measured to assess the inhibition of
JAK/STAT signaling pathways by tofacitinib. Numbers of
baseline pSTAT11 and pSTAT31 nuclei were greater in lesional
skin relative to nonlesional skin (lesional 5 median of 1290
pSTAT11 cells/mm2 of epidermis and median of 281 pSTAT31
cells/mm2 of epidermis; nonlesional 5 median of 155 pSTAT11
cells/mm2 of epidermis and median of 16.5 pSTAT31 cells/mm2
of epidermis; Fig 3). Rapid decreases in numbers of pSTAT11
and pSTAT31 nuclei in epidermal keratinocytes were observed
after 1 day of tofacitinib treatment (median of 332 pSTAT11
cells/mm2 of epidermis and median of 23 pSTAT31 cells/mm2
of epidermis, Fig 3), indicating a rapid and direct effect on kera-
tinocyte signaling. Placebo-treated patients continued to express
pSTAT1 and pSTAT3 at baseline levels in lesional skin
throughout the study (Fig 3).Psoriasis-related gene expression
Gene expression profiling was performed on Affymetrix
GeneChips to compare the expression of psoriasis-related genes
in the psoriasis transcriptome over time between tofacitinib- and
placebo-treated patients (Fig 4, A). Genes that were highly upre-
gulated in lesional skin at baseline showed a rapid decrease over
the first 2 weeks of tofacitinib treatment, and by week 12, expres-
sion levels were virtually identical to those of nonlesional skin
(Fig 4, A and C). Normalization of gene expression to nonlesional
levels was not seen in placebo-treated patients. The full set of
genes that were modulated by tofacitinib is listed in Table E2 in
this article’s Online Repository at www.jacionline.org.
Cytokine gene expression was measured by using quantitative
RT-PCR to confirm the gene array results. Fig 5 shows the expres-
sion of selected cytokine transcripts, along with corresponding
changes in CD11c1 DC and CD31 T-cell numbers. Reductions
in these cell levels appeared gradually over time, with significant
decreases in CD11c1 DC and CD31 T-cell numbers after 1 and
2 weeks of tofacitinib treatment (FDR < 0.1 and FDR < 0.05,
respectively; Fig 5, A and B). At week 12, DC and T-cell numbers
in tofacitinib-treated patients in lesional skin were similar to those
observed in nonlesional skin and were significantly reduced
versus those in placebo-treated patients (both FDR< 0.1). Expres-
sion of IL-12B, the cytokine p40 subunit common to IL-23 and
IL-12, which is released byDCs and activates TH17 and TH1 cells,
was significantly reduced after 2 weeks (FDR < 0.05; Fig 5, C).
Reduction in expression of the T-cell–related cytokines IFN-g
and IL-17 occurred relatively late, with significant reductions
observed after 4 weeks of treatment (FDR < 0.01 and
FDR < 0.001, respectively; Fig 5, D and E) after the onset of im-
provements in clinical and histologic features of psoriasis.
Expression of the IL-17–regulated molecules IL-19 and CCL20
were significantly reduced after 2 and 4 weeks (FDR < 0.05 and
FDR < 0.01, respectively; Fig 5, F and H). IL-22 expression
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Data presented as mean ± SEM; * or * indicates significance versus baseline; 
* above the x-axis in the tofacitinib plots indicates significant difference in change from baseline with tofacitinib versus placebo; 
* in the tofacitinib plots indicates significance of lesional versus nonlesional skin for all subjects (tofacitinib and placebo) at baseline.
P(time:treatment): P value of the F-test associated to the time-by-treatment interaction term in the mixed model.
FDR(Time:treatment): adjustment for multiplicity for P(time:treatment) using the Benjamini-Hochberg approach.
dCt, delta cycle threshold; FDR, false discovery rate; KRT16, keratin 16; NL, nonlesional skin; PASI, Psoriasis Area and Severity Index; 
SEM, standard error of the mean.
FIG 1. Clinical and histologic features of psoriasis over time with tofacitinib and placebo in lesional skin
(except where indicated). A, PASI score. B, Epidermal thickness. C, Ki671 nuclei. D, KRT16 expression.
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FIG 2. Histologic markers of psoriasis in a tofacitinib-treated patient. Hematoxylin and eosin (H&S) stain
shows a thickened epidermis with elongation into the dermis in lesional skin. KRT16 staining shows
increased keratinocyte proliferation in the epidermis, and CD3 and CD11c staining shows accumulation
of lymphocytes and DCs, respectively, in lesional versus nonlesional skin. Ki67 staining shows cell prolifer-
ation in the epidermis.
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(FDR < 0.1; Fig 5, G).
In light of the rapid reduction in nuclear staining for both pSTAT
and Ki67 in keratinocytes, which suggested a direct effect of
tofacitinib on keratinocytes, those genes that showed differential
expression at early time points weremore closely examined (Fig 4,
B, and Table I). MX dynamin-like GTPase 2 interferon response
gene (MX2), interferon-induced protein with tetratricopeptide re-
peats 1 (IFIT1), and ubiquitin-specific peptidase 18 (USP18)
expression was decreased in the first day of dosing (Fig 4, B),
which is consistent with the direct role of JAKs in IFN-a/b
signaling. Expression of keratinocyte proliferation markers,
including the S100 proteins, lipocalin-2 (LCN2), defensin beta
4A (DEFB4A), chemokine (C-X-Cmotif) ligand 1 (CXCL1), am-
phiregulin (AREG), and kallikrein-related peptidase (KLK) 6 and
10, was examined, and DEFB4A, CXCL1, AREG, and KLK10
expression decreased by week 2 (Table I) before reduction in IL-
17 expression. Expression of IL-19, IL-20, and IL-24, which are
produced by IL-17– and IL-22–stimulated keratinocytes and
signal in a JAK-dependent manner,19 was also reduced by week
2, before reduction of IL-17 expression (Table I). Expression of
IL-36a (IL36A) and IL-36g (IL36G), which are induced by IL-
17 and IL-22 and can drive keratinocyte proliferation and enhance
production of defensins and antimicrobial products,20 also
decreased by week 2 (IL-36g, TLDA only by week 2; Table I).
IL-37, an anti-inflammatory member of the IL-1 family that
competes with IL-18 to decrease expression of proinflammatorymolecules by keratinocytes,21 was expressed at low levels in le-
sional skin but rapidly increased with treatment (Table I).Association between clinical and histologic
improvement and gene expression changes
Although PASI scores showed significant improvement after
2 weeks of tofacitinib treatment (P < .001, see Fig E2, A, in this
article’s Online Repository at www.jacionline.org), significant
improvement from baseline in plaque characteristics (TPSS)
were observed as early as week 1 (P < .05, see Fig E2, B).
Placebo-treated patients also showed a significant decrease in
PASI scores from baseline, but changes in TPSSs were not signif-
icant. Psoriasis transcriptome gene expression (see Fig E2, C and
D) showed a gradual decreasewith tofacitinib, with significant re-
ductions from baseline versus placebo observed at week 1
(FDR < 0.1). Similar gene expression profiles were reported by
using TLDA and microarray analyses. Additional analyses of
changes in gene expression with tofacitinib treatment using
superenhancers of TH17, TH1, and TH2 cells are presented in
Fig E3 in this article’s Online Repository at www.jacionline.
org, with further details in the accompanying text.
A correlation analysis was carried out to assesswhether changes
in expression of psoriasis transcriptome genes and cytokine
expression were related to improved clinical and histologic
features of psoriasis with tofacitinib (Fig 6, A). The psoriasis tran-
scriptome meta-analysis of 3 psoriasis gene signatures (MAD3)
FIG 3. pSTAT1 and pSTAT3 expression in lesional biopsy specimens (except where indicated) from a
tofacitinib-treated responder and a placebo-treated nonresponder. A, pSTAT1 expression. B, pSTAT3
expression.
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KRT16 expression, and the MAD3 score was highly correlated
with epidermal thickness. IL-17 gene expression and MAD3
scores were both negatively correlated with PASI score
improvement. Gene expression measures showed stronger
correlation with histologic measures of disease activity (KRT16
and epidermal thickness) than with clinical assessment (PASI
score).
The relationship between changes in the psoriasis transcriptome
and IL-17 expression and the histologic response to tofacitinibwasfurther verified by comparison of psoriasis gene expression
between tofacitinib responders and nonresponders (Fig 6, B). Re-
sponders showed downregulation of gene expression in lesional
skin after 1 week of treatment, coinciding with clinical improve-
ments; gene expression levels approached those of nonlesional
skin after 4 to 12 weeks. In general, no change in gene expression
was observed in nonresponders over the course of the study. The
full set of genes that were differentially expressed between re-
sponders and nonresponders is listed in Table E3 in this article’s
Online Repository at www.jacionline.org.
FIG 4. Expression of psoriasis transcriptome genes. A, Heat map showing mean expression profiles for
genes in the psoriasis transcriptome with tofacitinib and placebo. B, Early effects of tofacitinib: heat map
showing genes significantly changed after 1 week of treatment (FDR < 0.05; fold change > 2). C, Comparison
with nonlesional skin for genes that were upregulated and downregulated in the psoriasis transcriptome in
lesional skin.
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FIG 5. Inflammatory cell and cytokine expression with tofacitinib in lesional skin (except where indicated).
A, DCs (CD11c1 cells). B, T cells (CD31 cells). C, IL-12B. D, IFN-g. E, IL-17. F, CCL20. G, IL-22. H, IL-19.
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TABLE I. Log2-fold changes from baseline in gene expression of selected keratinocytes proliferation markers induced by
tofacitinib
Log2-fold change (SEM) Day 1 Day 3 Week 1 Week 2 Week 4 Week 12
Microarray
IL-19 21.22 (0.85) 21.53 (0.85) 22.87 (0.85) 23.71 (0.85) 24.78 (0.85)§ 24.23 (0.88)§
IL-20 20.33 (0.40) 20.58 (0.40) 21.01 (0.40) 21.32 (0.40) 21.89 (0.40)§ 21.97 (0.41)§
IL-22 20.02 (0.38) 20.29 (0.38) 21.01 (0.38) 20.99 (0.38)* 21.49 (0.38) 21.35 (0.40)
IL-24 20.74 (0.39) 20.74 (0.39) 20.98 (0.39) 21.56 (0.39) 22.01 (0.39)§ 21.72 (0.40)§
IGF1R 0.25 (0.23) 0.36 (0.23) 0.54 (0.23) 0.64 (0.23)* 1.02 (0.23)§ 0.98 (0.24)§
TNF 0.17 (0.26) 0.63 (0.26) 0.07 (0.26) 20.10 (0.26) 20.30 (0.26) 20.65 (0.27)
AREG 20.10 (0.35) 20.64 (0.35) 21.02 (0.35)* 21.38 (0.35) 22.32 (0.35)§ 22.35 (0.36)§
IL-6 20.39 (0.44) 20.46 (0.44) 20.79 (0.44) 21.05 (0.44) 21.27 (0.44) 20.90 (0.45)*
IL-36A 20.80 (0.79) 21.84 (0.79) 21.98 (0.79) 22.78 (0.79) 24.13 (0.79)§ 24.38 (0.82)§
IL-36G 20.13 (0.46) 20.40 (0.46) 20.70 (0.46) 21.09 (0.46) 22.58 (0.46)§ 23.08 (0.48)§
IL-37 0.65 (0.49) 0.56 (0.49) 1.16 (0.49) 1.53 (0.49) 2.15 (0.49)§ 2.25 (0.50)§
IL-1B 0.09 (0.58) 20.21 (0.58) 21.26 (0.58) 21.58 (0.58)* 22.99 (0.58)§ 22.81 (0.60)§
S100A8 20.06 (0.40) 20.03 (0.40) 20.16 (0.40) 20.40 (0.40) 21.12 (0.40) 21.98 (0.41)§
S100A9 20.19 (0.77) 20.31 (0.77) 20.70 (0.77) 21.24 (0.77) 23.17 (0.77)§ 24.58 (0.79)§
S100A12 20.08 (0.96) 20.43 (0.96) 21.01 (0.96) 22.25 (0.96) 25.55 (0.96)§ 25.86 (1.00)§
LCN2 20.01 (0.81) 20.25 (0.81) 20.63 (0.81) 21.24 (0.81) 23.04 (0.81) 24.22 (0.84)§
DEFB4A 20.02 (1.05) 20.14 (1.05) 20.46 (1.05) 22.00 (1.05) 24.47 (1.05)§ 25.82 (1.09)§
CXCL1 20.58 (0.77) 21.06 (0.77) 22.10 (0.77)* 23.10 (0.77) 24.55 (0.77)§ 24.26 (0.80)§
KLK6 20.25 (0.89) 20.97 (0.89) 21.30 (0.89) 21.79 (0.89) 23.34 (0.89) 23.74 (0.92)§
KLK10 20.52 (0.33) 20.53 (0.33) 20.71 (0.33) 20.92 (0.33)* 21.82 (0.33)§ 22.46 (0.34)§
TLDA
IL-19 20.82 (1.51) 21.92 (1.51) 22.80 (1.51) 24.65 (1.51) 27.79 (1.51)§ 26.95 (1.51)§
IL-20 20.12 (1.23) 20.70 (1.23) 22.19 (1.23) 22.92 (1.23) 25.22 (1.23)§ 25.12 (1.23)§
IL-22 20.91 (1.22) 20.87 (1.22) 22.63 (1.22) 23.61 (1.22) 25.22 (1.22)§ 24.22 (1.22)
IL-24 21.63 (1.17) 22.13 (1.17) 22.27 (1.17) 23.59 (1.17) 25.44 (1.17)§ 25.36 (1.17)§
IGF1R – – – – – –
TNF 0.02 (0.26) 0.36 (0.26) 20.02 (0.26) 20.01 (0.26) 20.36 (0.26)* 20.37 (0.26)*
AREG 0.11 (0.30) 20.20 (0.30) 20.54 (0.30) 20.80 (0.30) 21.70 (0.30)§ 21.81 (0.30)§
IL-6 0.14 (0.55) 0.47 (0.55) 0.12 (0.55) 20.30 (0.55) 20.53 (0.55) 20.44 (0.55)
IL-36A 20.18 (1.48) 21.09 (1.48) 21.75 (1.48) 23.96 (1.48) 27.96 (1.48)§ 28.30 (1.48)§
IL-36G 0.00 (0.55) 20.25 (0.55) 20.77 (0.55) 21.33 (0.55) 23.06 (0.55)§ 23.54 (0.55)§
IL-37 0.75 (0.43) 0.85 (0.43) 1.14 (0.43) 1.42 (0.43) 2.00 (0.43)§ 2.16 (0.43)§
IL-1B 0.00 (0.61) 20.07 (0.61) 21.26 (0.61)* 21.26 (0.61)* 22.32 (0.61)§ 22.38 (0.61)§
S100A8 20.08 (1.00) 20.48 (1.00) 21.09 (1.00) 22.13 (1.00)* 24.86 (1.00)§ 26.24 (1.00)§
S100A9 20.06 (0.97) 20.54 (0.97) 21.06 (0.97) 22.04 (0.97)* 24.77 (0.97)§ 26.25 (0.97)§
S100A12 0.08 (1.01) 20.36 (1.01) 20.96 (1.01) 22.00 (1.01)* 25.22 (1.01)§ 25.80 (1.01)§
LCN2 0.23 (0.83) 20.08 (0.83) 20.83 (0.83) 21.52 (0.83)* 23.48 (0.83)§ 24.20 (0.83)§
DEFB4A 20.12 (1.50) 20.85 (1.50) 21.72 (1.50) 23.78 (1.50) 27.49 (1.50)§ 29.27 (1.50)§
CXCL1 20.55 (0.66) 20.44 (0.66) 21.56 (0.66)* 22.12 (0.66) 23.48 (0.66)§ 22.95 (0.66)§
KLK6 20.12 (0.79) 20.86 (0.79) 21.22 (0.79) 21.78 (0.79) 23.03 (0.79)§ 23.43 (0.79)§
KLK10 20.29 (0.37) 20.46 (0.37) 20.72 (0.37) 20.95 (0.37) 21.96 (0.37)§ 22.53 (0.37)§
AREG, Amphiregulin; CXCL, chemokine (C-X-C motif) ligand; IGF1R, insulin-like growth factor 1 receptor; KLK, kallikrein-related peptidase; LCN, lipocalin; S100, s100
calcium-binding protein; TNF, tumor necrosis factor.
*FDR < 0.1.
FDR < 0.05.
FDR < 0.001.
§FDR < 0.0001.
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Four patients (n5 2 per group) experienced a total of 8 adverse
events. Most adverse events were mild in severity (6 mild, 1
moderate, and 1 severe). One case of cholelithiasis in a placebo-
treated patient was classified as a serious adverse event, resulting
in temporary discontinuation of study medication.DISCUSSION
Psoriasis is characterized by a pathogenic cycle in which
inflammatory T-cell and DC infiltrates within the skin release
cytokines, leading to the activation and proliferation ofkeratinocytes.2 These activated keratinocytes release chemo-
kines, which in turn recruit and activate more myeloid DCs and
TH1 and TH17 cells to continue the pathogenic cycle.
2 The results
presented here suggest that tofacitinib has a unique multitiered
mechanism of action with an early direct effect on keratinocytes.
This mechanism manifests itself histologically through a rapid
decrease in markers of keratinocyte proliferation and epidermal
thickness and a normalization of inflammatory infiltrate, eventu-
ally leading to a decrease in the IL-23/TH17 axis that drives ker-
atinocyte dysregulation (Fig 7).
We have provided the following evidence for a direct effect
of tofacitinib on keratinocytes. At baseline, levels of nuclear
FIG 6. A, Correlation between clinical (PASI score) and histologic (KRT16 level and epidermal thickness)
outcomes and MAD3 psoriasis scores and IL-17 scores. B, Heat map showing mean expression profiles
by histologic response to tofacitinib for genes in the psoriasis transcriptome that differ between responders
and nonresponders at week 12 (FDR < 0.25; fold change > 2).
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increased in keratinocytes in lesional skin and dramatically
reduced after 1 day of tofacitinib treatment. This blockade of
JAK signaling in keratinocytes led, both directly and indirectly, to
reduced signaling of the IL-20/24 family of cytokines, including
IL-19. JAK inhibition also reduced CCL20 production by
keratinocytes. Consistent with this direct effect on keratinocytes,
levels of inflammatory mediators produced by keratinocytes,
including defensins (or AMPs) and IL-36, were reduced within
the first 2 weeks of therapy. In patients with psoriasis, expression
of cytokines and other inflammatory molecules by keratinocytes
recruits additional CD11c1DCs and CD31 T cells to lesion sites,
leading to perpetuation of the inflammatory response.22 By inhib-
iting production of these molecules and inhibition of JAK-
dependent cytokines, such as IL-7 and IL-15 (which promote sur-
vival of resident DCs and T cells23), tofacitinib treatment led to a
reduction in pathologic DC and T-cell numbers in psoriatic le-
sions after 1 to 2 weeks. After a reduction in T-cell and DC
numbers in lesional skin, expression of IL-17, IL-22, and IFN-g
was reduced by week 4. After 12 weeks of tofacitinib treatment,
residual T-cell and DC numbers approximated those in pretreat-
ment nonlesional skin. Therefore tofacitinib appeared to selec-
tively modulate inflammation-related, but not skin-resident,
leukocytes. In addition, the observed reduction in IL-17 andIFN-g expression might also, in part, have resulted from blockade
of the JAK signaling required for TH1 and TH17 cell differentia-
tion, as seen in preclinical models.7
In assessing the mechanism of action of tofacitinib, it is
important to consider the level of cytokine inhibition achievable
at the clinical dose of 10 mg twice daily. In studies using cells
of hematopoietic lineage, tofacitinib preferentially inhibited
cytokines that signaled through JAK1, JAK3, or both, with less
potency against JAK2- and tyrosine kinase 2–dependent cyto-
kines (eg, IL-23).6 Dosed at 10 mg twice daily, tofacitinib in-
hibited common g-chain cytokines, such as IL-21, by
approximately 70%; IFN-a by 80%; and IL-23 by 30% during
the dosing period. At the minimum tofacitinib plasma concen-
tration each day, the predicted inhibition was significantly
less.24,25 In studies using cultured keratinocytes stimulated
with IL-22, the measured half-maximal inhibitory concentration
predicted that IL-22 would be inhibited by an average of 30%
through the day (data on file, Pfizer Inc), although more com-
plete inhibition was observed in the biopsy specimens here.
Although tofacitinib does not directly inhibit IL-17, it does
inhibit TH17 cell differentiation by inhibiting IL-21, IL-6,
and, to a lesser extent, IL-23.7 Therefore, at the clinical dose
studied here, efficacy was derived from partial inhibition of
multiple cytokines.
FIG 7. Tofacitinib has a unique multitiered mechanism of action with an early direct effect on keratinocytes.
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ments in clinical disease severity and changes at the cellular and
genomic levels in patients. We showed that tofacitinib reduced
expression of psoriasis transcriptome genes, with changes
occurring within 1 week and before reduction of IL-17 levels.
In addition, the correlation between the MAD3 psoriasis
transcriptome score and epidermal thickness was greater than
the correlation between epidermal thickness and the IL-17
score, suggesting that additional pathways than IL-17 were
targeted by tofacitinib that were important for early disease
resolution.
A potential limitation of this study was the relatively small
number of patients in the placebo group (n5 3). Variable changes
were observed among those patients for clinical end points, which
is likely related to natural fluctuations in psoriasis severity and
PASI scores over time. Despite variable placebo group data, the
reported correlation of clinical and histologic measures with
MAD3 scores and IL-17 levels supports the conclusion that the
observed molecular changes are associated with improvements in
clinical and histologic outcomes.
In summary, these results demonstrate that partial inhibition of
JAK signaling by tofacitinib results in a multitiered intervention
in the cycle of psoriasis pathogenesis, with a direct effect on
dysregulated keratinocytes, reduction in inflammatory infiltrate,
and, ultimately, normalization of the IL-23/TH17 axis.
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Key messages
d Tofacitinib treatment leads to rapid attenuation of the
increased JAK/STAT signaling seen in psoriatic
keratinocytes.
d T-cell and DC infiltrates are increased in lesional skin. To-
facitinib reduced cell numbers to those seen in nonlesional
skin, with a concurrent reduction in levels of cytokines
that support the IL-23/TH17 inflammatory pathway.
d Improvements in clinical and histologic features with to-
facitinib are strongly associated with changes in expres-
sion of psoriasis-related genes and reduction in IL-17
expression.REFERENCES
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